Biography
Interests
Kazumi Fujioka
Department of Radiology, Nihon University School of Medicine, Tokyo, Japan
*Correspondence to: Dr. Kazumi Fujioka, Department of Radiology, Nihon University School of Medicine, Tokyo, Japan.
Copyright © 2021 Dr. Kazumi Fujioka. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
The emerging coronavirus disease 2019 (COVID-19) by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a worldwide outbreak, leading to a major threat to public health. The respiratory failure from acute respiratory distress syndrome (ARDS) as the major cause of mortality and multi-organ failure as other causes of mortality have been revealed in patients with COVID-19. The expression of angiotensin-converting enzyme 2 (ACE2) in the respiratory epithelium, vascular endothelium, and other cell types are recognized and can play a role as a primary mechanism of SARS-CoV-2 entry and infection process. It has been described that host cells infected by SARS-CoV-2 cause ARDS, sequentially stimulating the immune response or cytokine storm, vascular damage, and thrombosis in all arterial beds. It has been thought that clinical manifestations of COVID-19 in the severe stage present an endothelial disease and a systemic disease. In this article, the current knowledges of the link between endothelial dysfunction and SARS-CoV-2 infection have been reviewed. A close association between endothelial dysfunction and SARS-CoV-2 infection has been indicated in patients with COVID-19. The author also emphasizes that COVID-19 may be an endothelial disease and a systemic disease especially in the severe stage. In addition to antiviral and anti-inflammatory treatments, a new therapeutic strategy of use of nitric oxide (NO) focusing on the vascular tone of the endothelial dysfunction may be a potential treatment in patient with COVID-19 especially in the moderate and severe stages.
Introduction
The respiratory failure from ARDS is the major cause of mortality [1] and multi-organ failure is regarded
as other causes of mortality in patients with COVID-19 [2]. The worst outcomes have been reported in
individuals with comorbidities such as hypertension, diabetes mellitus, obesity, and men [3]. Some studies
have suggested hypercoagulability and increased inflammatory markers in patients with COVID-19 [4].
Amraei et al. [5] indicated the endothelial cell injury in lung organ and periphery caused by direct SARSCoV-
2 infection. Some studies provided that COVID-19 is an endothelial disease and a systemic disease in
the severe stages. The author will review the current knowledges of a link between endothelial dysfunction
and SARS-CoV-2 infection in detail.
Emerging COVID-19 Global Pandemic
The respiratory failure from ARDS is the major cause of mortality [1] and multi-organ failure involving heart
and kidneys are regarded as other causes of mortality in patients with COVID-19 [2]. It has been described
that in general, subjects with comorbidities such as hypertension, diabetes mellitus, obesity, and men have
caused worst outcomes [3]. Some studies have suggested hypercoagulability such as raised D dimer and von
Willebrand factor (VWF) value, and increased inflammatory markers including CRP, ferritin, interleukin
(IL)-6, IP-10, MCP1, MIP1A, and TNF-α in patients with COVID-19 [4]. The theory has been provided
that SARS-CoV-2 infection causes the endothelial cell injury in the lung and periphery. Endothelial cell
injury can also activate the coagulation system and immune response enhances endothelial dysfunction [5].
It has been known that the raised VWF level is associated with endothelial dysfunction [5]. The notion that
SARS-CoV-2 infection has induced endothelial dysfunction and/or damage was supported by the study of
the elevated VWF level in patients with COVID-19 [6]. Marini et al. [7] have reported that the chest-X
ray or computed tomography (CT) scan showed alveolar infiltrate appearances and the respiratory distress
with important vascular insult in patients with COVID-19. They also noted that COVID-19 is a systemic
disease that primarily affects the vascular endothelial cells [7].
Endothelial Function Assessed by FMD and RH-PAT Examinations
Flow-mediated vasodilation (FMD) and nitroglycerin-mediated vasodilation (NMD) in the brachial artery
is a potential tool for assessing vascular endothelial and vascular smooth muscle cell (VSMC) function in
atherosclerosis status [8]. The author has described several reports on the diseases of migraine, cardiovascular
disease (CVD), chronic kidney disease (CKD), dyslipidemia, and aging liver [9-19] using FMD and NMD
test. Another methodology estimating endothelial function implies the reactive hyperemia peripheral artery
tonometry (RH-PAT) assessed by digital vascular function [20].
Endothelial Dysfunction Through RAS in Patients With COVID-19
The emerging COVID-19 global pandemic caused by SARS-CoV-2 infection has affected a major threat to
public health. The expression of angiotensin-converting enzyme 2 (ACE2) which serves as an essential role
in renin-angiotensin system (RAS) was recognized in the respiratory epithelium, vascular endothelium, and
other cell types. It has been also considered as a primary mechanism of SARS-CoV-2 entry and infection
processes. It has been known that SARS-CoV-2 through the surface spike glycoprotein interacts with
ACE2 and invades and infects the host cells. Host cells infected by SARS-CoV-2 have caused ARDS,
sequentially stimulating the immune response or cytokine storm and vascular damage. SRAS-CoV-2
infection has induced endothelial cell damage and exacerbated endothelial dysfunction which has been
regarded as atherosclerotic condition. Amraei et al. [5] have supported the notion that a relationship between
the presence of the endothelial dysfunction and endothelial damage caused by SARS-CoV-2 in COVID-19
associated mortality. They also concluded that ARDS induced by cytokine storm and/or vascular damage
is the most critical manifestation in patient with COVID-19. The presence of endothelial dysfunction
combines with the vascular damage caused by SARS-CoV-2 in patient with atherosclerotic condition,
thereby leading to severe morbidity and mortality [5]. While, Hoffmann et al. [21] suggested that SARSCoV-
2 infection depends on ACE2 and TMPRSS2 as host cell factors. They also indicated that antibodies
against SARS-CoV spike may offer the protection against SARS-CoV-2 [21].
Genomics Sequence in SARS-CoV-2
There is an envelope, a helical capsid, and a single-stranded, positive-sense RNA genome with a length
of 27-32 kb in coronaviruses [5,22]. It has been revealed that the whole genome of SARS-CoV-2 was
sequenced [23]. The 5’ end of the viral genome encodes two polyproteins such as pp1a and pp1ab, leading
to generation of 16 non-structual protein. While, the 3’ end of the genome of SARC-CoV-2 encodes four
structural proteins including spike (S), envelope (E), matrix/membrane (M), and nucleocapsid (N) [5,23].
It has been noted that the amino acid sequence between SARS-CoV and SARS-CoV S-proteins which
are important for entry and infection processes of coronaviruses was revealed [5,23]. Similar to human
coronavirus NL63 (hCoV-NL63) [24] and SARS-CoV [25], ACE2 was recognized as a receptor for
SARS-CoV-2 [26]. While the spike protein encoded by the Middle East respiratory syndrome (MERSCoV)
recognizes CD26 as a receptor for cellular entry and infection [5,27].
A Link Between Endothelial Dysfunction and SARS-CoV-2 Infection
Gladka et al. [28] noted that the primary cell type involved in the initiation and propagation of ARDS
caused by SARS-CoV-2 infection is endothelial cell. As a result, the severe endothelial injury and widespread
thrombosis occur. The cytokine storm observed in severe COVID-19 patients contributes to destruction of
endothelium, leading to cause ARDS, multi-organ failure, and death [29,30]. It is well known that the
endothelium regulates the control of haemostasis, fibrinolysis, vascular tone or vasomotion, inflammation,
oxidative stress, vascular permeability, and structure. Libby et al. [29] described that SARS-CoV-2 induces
the protean clinical manifestations from head to toe, affecting the multiple organ systems including the
lungs, heart, brain, kidney, and vasculature. With respect to the clinical course in COVID-19, in the initial phase, the type I and II pneumocytes and alveolar macrophages participates in the initiation of infection.
The disordered endothelial function has gradually promoted the destructive forces of SARS-CoV-2 in the
lung as elsewhere. It has been described that impaired endothelial barrier function and IL-stimulation
sequentially lead to a cytokine storm and aggravation of the ARDS in patients with COVID-19. It has been
thought that COVID-19 in the advanced stage, represents an endothelial disease involving a cytokine storm
and/or an inflammatory phenomenon. With respect to the pathophysiological mechanism of a cytokine
storm, IL-1 induces its own gene expression and that of other pro-inflammatory cytokines including
TNF-α and IL-6. In result, the induction of IL-6 which is produced by IL-1 provides another amplification
loop, leading to the cytokine storm. In the advanced stage, SARS-CoV-2 serve as a destructive action
beyond the lung organ, representing that predispose to thrombosis in the pulmonary circulation and the
cerebral circulation. Furthermore, it has been noted that thrombosis can occur in all arterial beds within the
microvasculature [29].
The Presence of SARS-CoV-2 in Endothelium
Varga et al. [31] described that pathological appearances of the endothelial cell dysfunction in COVID-19
represent the viral elements of the endothelial cells and diffuse endothelial inflammation. Based on the proof
of the viral involvement and host inflammatory response, it has been suggested that SARS-CoV-2 infection
predisposes the occurrences of endotheliitis in several organs [31]. They additionally mentioned that
endothelial cell injury has developed by induction of apoptosis and pyroptosis in patients with COVID-19
[31]. They concluded that COVID-19-endotheliitis is regarded as the systemic impaired microcirculatory
function in different vascular beds and their sequelae of injury [31]. In dermatological field, Colmenero
et al. [32] have reported that immunohistochemical and electron microscopic features of SARS-CoV-2
infection in endothelial cells indicate that these lesions are part of the spectrum of COVID-19. They suggest
that the pathophysiology of COVID-19 chilblains is due to the vascular damage caused by virus infection
and secondary ischaemia. They also supported the notion that widespread endothelial infection induced by
SARS-CoV-2 serve as a pathogenic role particularly in the severe types in patients with COVID-19.
Therapeutic Strategy for COVID-19
In the global pandemic, vaccine and antiviral drugs have been prioritized until now. The multiple other
mechanisms which represent Achilles heels of SARS-CoV-2 infection have been reported. The recent study
suggested that Camostat mesylate as TMPRSS2 inhibitor decreases SARS-CoV-2-spike-driven entry into
lung epithelial cells [5,21]. Blocking the ectodomain shedding of ACE2 provides a unique treatment in
patients with COVID-19. While inhibition of SARS-CoV-2’s own peptidases such as 3CLpro and PLpro
is another essential aspect of treatment targets against SRARS-CoV-2 and α-ketoamide inhibitor which
inhibits SARS-CoV-2 RNA synthesis has been also identified [33]. While, the study provided that NO
level and bioavailability decreased in patients with COVID-19, indicating exogenous supplementation of
NO might assist prevention and therapeutic of infection [34]. In addition to antiviral and anti-inflammatory
drugs, a new strategy of use of NO focusing on the vasomotion or vascular tone in endothelial dysfunction
may be an essential therapeutic in patient with COVID-19.
In Summary
Clinical course in COVID-19 represented the initial infection of pneumocytes, leading to disordered
endothelial function, impaired endothelial barrier function and IL-stimulation, cytokine storm and vascular
damage, and thrombosis in all arterial beds, thereby suggesting that COVID-19 may be an endothelial
disease and a systemic disease in severe stage. A close relationship between endothelial dysfunction
including haemostasis, fibrinolysis, vascular tone or vasomotion, inflammation, oxidative stress, and vascular
permeability, and SARS-CoV-2 infection has been suggested in patients with COVID-19. Pathologically,
the proof of the presence of viral elements revealed that SARS-CoV-2 infection predisposes the induction
of endotheliitis in several organs. With respect to the therapeutic, a new strategy of use of NO focusing on
the vascular tone or vasomotion in endothelial dysfunction may be an essential treatment in patient with
COVID-19.
Conclusion
1. A close relationship between endothelial dysfunction and SARS-CoV-2 infection has been suggested in
patients with COVID-19.M
2. The author also emphasizes that COVID-19 may be an endothelial disease and a systemic disease
especially in the severe stage.
3. In addition to antiviral and anti-inflammatory treatments, a new treatment strategy of use of NO
focusing on the vascular tone of the endothelial dysfunction may be an essential therapeutic in patient with
COVID-19 especially in the moderate and severe stages.
Bibliography
Hi!
We're here to answer your questions!
Send us a message via Whatsapp, and we'll reply the moment we're available!